Latest developments in MUC1 immunotherapy.

about

O-linked mucin-type glycosylation in breast cancer Improving Immunotherapy Through Glycodesign

P2860

Q57107715-FBC46F62-63A9-4EE0-BE44-FBEC5B51F9FD Q59132146-79F7F277-2850-499C-8344-557AE0DEE94E

P2860

Latest developments in MUC1 immunotherapy.

Item

http://www.wikidata.org/entity/Q55417304

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Latest developments in MUC1 immunotherapy.

@en

Latest developments in MUC1 immunotherapy.

@nl

type

Item

label

Latest developments in MUC1 immunotherapy.

@en

Latest developments in MUC1 immunotherapy.

@nl

prefLabel

Latest developments in MUC1 immunotherapy.

@en

Latest developments in MUC1 immunotherapy.

@nl

P1476

Latest developments in MUC1 immunotherapy

@en

P2093

Joyce Taylor-Papadimitriou

http://www.w3.org/2001/XMLSchema#string

Richard Beatson

http://www.w3.org/2001/XMLSchema#string

Rosalind Graham

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

Mucins in cancer: function, prognosis and therapy

The development of synthetic antitumour vaccines from mucin glycopeptide antigens

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.

Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen

Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.

Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium.

Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells.

Cloning and sequencing of a human pancreatic tumor mucin cDNA.

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

P304

659-668

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BST20170400

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joy M Burchell

P5008

ScienceSource

P577

2018-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29784646

http://www.w3.org/2001/XMLSchema#string

P921

P932

6008591

http://www.w3.org/2001/XMLSchema#string

Latest developments in MUC1 immunotherapy.

about

P2860

P2860

Latest developments in MUC1 immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932